S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   287.36 (-0.77%)
AAPL   136.99 (-0.26%)
MSFT   251.33 (-0.72%)
FB   192.70 (+0.74%)
GOOGL   2,170.04 (-1.70%)
AMZN   2,146.79 (+0.02%)
TSLA   658.09 (-7.24%)
NVDA   165.36 (-3.43%)
BABA   86.59 (-1.25%)
NIO   16.34 (-1.92%)
AMD   92.69 (-4.12%)
CGC   5.51 (-6.13%)
MU   68.40 (-1.44%)
T   20.34 (+0.64%)
GE   75.16 (-0.77%)
F   12.47 (-2.96%)
DIS   102.12 (-0.99%)
AMC   11.92 (-8.87%)
PFE   52.44 (+3.53%)
PYPL   80.35 (-1.14%)
NFLX   185.33 (+1.01%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   287.36 (-0.77%)
AAPL   136.99 (-0.26%)
MSFT   251.33 (-0.72%)
FB   192.70 (+0.74%)
GOOGL   2,170.04 (-1.70%)
AMZN   2,146.79 (+0.02%)
TSLA   658.09 (-7.24%)
NVDA   165.36 (-3.43%)
BABA   86.59 (-1.25%)
NIO   16.34 (-1.92%)
AMD   92.69 (-4.12%)
CGC   5.51 (-6.13%)
MU   68.40 (-1.44%)
T   20.34 (+0.64%)
GE   75.16 (-0.77%)
F   12.47 (-2.96%)
DIS   102.12 (-0.99%)
AMC   11.92 (-8.87%)
PFE   52.44 (+3.53%)
PYPL   80.35 (-1.14%)
NFLX   185.33 (+1.01%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   287.36 (-0.77%)
AAPL   136.99 (-0.26%)
MSFT   251.33 (-0.72%)
FB   192.70 (+0.74%)
GOOGL   2,170.04 (-1.70%)
AMZN   2,146.79 (+0.02%)
TSLA   658.09 (-7.24%)
NVDA   165.36 (-3.43%)
BABA   86.59 (-1.25%)
NIO   16.34 (-1.92%)
AMD   92.69 (-4.12%)
CGC   5.51 (-6.13%)
MU   68.40 (-1.44%)
T   20.34 (+0.64%)
GE   75.16 (-0.77%)
F   12.47 (-2.96%)
DIS   102.12 (-0.99%)
AMC   11.92 (-8.87%)
PFE   52.44 (+3.53%)
PYPL   80.35 (-1.14%)
NFLX   185.33 (+1.01%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   287.36 (-0.77%)
AAPL   136.99 (-0.26%)
MSFT   251.33 (-0.72%)
FB   192.70 (+0.74%)
GOOGL   2,170.04 (-1.70%)
AMZN   2,146.79 (+0.02%)
TSLA   658.09 (-7.24%)
NVDA   165.36 (-3.43%)
BABA   86.59 (-1.25%)
NIO   16.34 (-1.92%)
AMD   92.69 (-4.12%)
CGC   5.51 (-6.13%)
MU   68.40 (-1.44%)
T   20.34 (+0.64%)
GE   75.16 (-0.77%)
F   12.47 (-2.96%)
DIS   102.12 (-0.99%)
AMC   11.92 (-8.87%)
PFE   52.44 (+3.53%)
PYPL   80.35 (-1.14%)
NFLX   185.33 (+1.01%)
NASDAQ:ARQT

Arcutis Biotherapeutics (ARQT) Stock Forecast, Price & News

$20.52
+0.67 (+3.38%)
(As of 05/20/2022 03:51 PM ET)
Add
Compare
Today's Range
$19.73
$20.83
50-Day Range
$15.74
$21.99
52-Week Range
$13.59
$29.37
Volume
18,295 shs
Average Volume
257,052 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.28
30 days | 90 days | 365 days | Advanced Chart
Receive ARQT News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Arcutis Biotherapeutics logo

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARQT
Fax
N/A
Employees
147
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.94 per share

Profitability

Net Income
$-206.36 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
31,365,000
Market Cap
$1.06 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/20/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.46 out of 5 stars

Medical Sector

168th out of 1,420 stocks

Pharmaceutical Preparations Industry

67th out of 679 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -













Arcutis Biotherapeutics (NASDAQ:ARQT) Frequently Asked Questions

Is Arcutis Biotherapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arcutis Biotherapeutics stock.
View analyst ratings for Arcutis Biotherapeutics
or view top-rated stocks.

When is Arcutis Biotherapeutics' next earnings date?

Arcutis Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Arcutis Biotherapeutics
.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) released its quarterly earnings results on Thursday, May, 5th. The company reported ($1.27) earnings per share for the quarter, beating analysts' consensus estimates of ($1.50) by $0.23.
View Arcutis Biotherapeutics' earnings history
.

What price target have analysts set for ARQT?

4 equities research analysts have issued 1-year target prices for Arcutis Biotherapeutics' stock. Their forecasts range from $37.00 to $57.00. On average, they anticipate Arcutis Biotherapeutics' stock price to reach $46.33 in the next year. This suggests a possible upside of 125.8% from the stock's current price.
View analysts' price targets for Arcutis Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Arcutis Biotherapeutics' key executives?
Arcutis Biotherapeutics' management team includes the following people:
  • Mr. Todd Franklin Watanabe M.A., Pres, CEO & Director (Age 54, Pay $940.2k) (LinkedIn Profile)
  • Dr. Bhaskar Chaudhuri Ph.D., Co-Founder & Independent Director (Age 67, Pay $60.58k) (LinkedIn Profile)
  • Mr. Scott L. Burrows, CFO & Principal Accounting Officer (Age 45, Pay $617.87k) (LinkedIn Profile)
  • Dr. David W. Osborne Ph.D., Chief Technical Officer (Age 61, Pay $584.55k)
  • Dr. Patrick E. Burnett M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 50, Pay $700.1k)
  • Mr. Matthew Richard Moore, Sr. VP & Chief Bus. Officer (Age 48, Pay $560.07k)
  • Ms. Patricia A. Turney, Sr. VP of Operations (Age 55) (LinkedIn Profile)
  • Mr. Eric McIntyre, Head of Investor Relations
  • Ms. Courtney Barton, Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer (Age 39)
  • Mr. Masaru Matsuda Esq., J.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

(ARQT) raised $125 million in an IPO on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

What is Arcutis Biotherapeutics' stock symbol?

Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Frazier Life Sciences Management L.P. (16.40%), BlackRock Inc. (8.39%), Vanguard Group Inc. (2.98%), State Street Corp (2.31%), American Century Companies Inc. (1.02%) and Ensign Peak Advisors Inc (0.96%). Company insiders that own Arcutis Biotherapeutics stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends for Arcutis Biotherapeutics
.

Which institutional investors are selling Arcutis Biotherapeutics stock?

ARQT stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Sectoral Asset Management Inc., Northern Trust Corp, Walleye Capital LLC, Metropolitan Life Insurance Co NY, Royal Bank of Canada, California State Teachers Retirement System, and ProShare Advisors LLC. Company insiders that have sold Arcutis Biotherapeutics company stock in the last year include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows, and Todd Franklin Watanabe.
View insider buying and selling activity for Arcutis Biotherapeutics
or view top insider-selling stocks.

Which institutional investors are buying Arcutis Biotherapeutics stock?

ARQT stock was acquired by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., GW&K Investment Management LLC, Dimensional Fund Advisors LP, Ensign Peak Advisors Inc, 1492 Capital Management LLC, State Street Corp, Hsbc Holdings PLC, and American Century Companies Inc..
View insider buying and selling activity for Arcutis Biotherapeutics
or or view top insider-buying stocks.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcutis Biotherapeutics' stock price today?

One share of ARQT stock can currently be purchased for approximately $20.52.

How much money does Arcutis Biotherapeutics make?

Arcutis Biotherapeutics has a market capitalization of $1.06 billion. The company earns $-206.36 million in net income (profit) each year or ($4.670010) on an earnings per share basis.

How many employees does Arcutis Biotherapeutics have?

Arcutis Biotherapeutics employs 147 workers across the globe.

What is Arcutis Biotherapeutics' official website?

The official website for Arcutis Biotherapeutics is www.arcutis.com.

How can I contact Arcutis Biotherapeutics?

Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The company can be reached via phone at 805-418-5006 or via email at [email protected].

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.